MC1R comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-12-18. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory treatment varies by country. In the United States, melanotan-2 is not approved for any indication, and products marketed for human use fall outside the approved drug framework. Some other jurisdictions have placed it under prescription controls or listed it as a prohibited or restricted substance. Online listings frequently describe the material as a research chemical, a category that does not carry the same manufacturing and labelling requirements as approved medicines.
Solid peptide material is generally stable when kept cold and dry. Common practice is storage at -20 degrees Celsius or lower, with desiccant and protection from light. Repeated freeze-thaw cycles and exposure to moisture are associated with degradation, aggregation, or loss of material. Once dissolved, stability depends on solvent, concentration, and temperature, and solutions are usually treated as short-lived unless stability data support longer periods. Handling notes typically emphasise minimising time at ambient temperature.
Identity and purity are assessed with chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the target peptide from related impurities and degradation products, and the resulting retention time is compared against a reference standard. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass. Amino acid analysis or peptide mapping can provide additional sequence-level confirmation when required. Results are only as reliable as the reference materials used alongside them.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
| Property | Value | Notes |
|---|---|---|
| Solid-state storage | -20 degrees Celsius or lower | Desiccated and protected from light |
| Solution stability | Short and method-dependent | Confirm by stability testing |
| Purity assessment | Reversed-phase HPLC | Reported as area percent |
| Identity confirmation | LC-MS or comparable method | Mass match against expected value |
| Common synonyms | MT-II; melanotan II | Informal and catalogue names |
Regulatory status varies by jurisdiction, and the substance is frequently described as unapproved for therapeutic use. Some authorities classify it alongside prescription-only medicines or controlled categories, while others address it through general consumer protection rules. Analytical surveys have reported mismatches between label claims and measured content in products sold online, although the scope of such testing is limited. Whether these discrepancies are widespread remains an open question. Discussion in the literature therefore tends to combine chemistry, supply-chain observation and policy analysis.
The material is commonly handled as a lyophilized powder in sealed vials. The solid dissolves readily in water and in polar organic solvents, producing a clear solution after reconstitution. Light, heat and repeated freeze-thaw cycles are the concerns most often raised in handling guidance, because peptide bonds and the constrained ring can degrade. Working solutions are generally prepared fresh, and material left in solution is treated as less stable than the dry form. These properties shape how laboratories store and aliquot reference material.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry. Retention time supports identity, while the mass spectrum confirms the molecular weight of the intact peptide. Purity is frequently reported as a percentage of total peak area, a figure that depends on the wavelength, column and gradient used. Impurity profiling may also look for truncated sequences, oxidised forms and residual counterions. Amino acid analysis and peptide mapping provide orthogonal confirmation when required.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
Identification in laboratories relies on reversed-phase liquid chromatography coupled with tandem mass spectrometry, with product-ion spectra compared against a certified reference standard. High-resolution mass spectrometry supplies accurate mass confirmation, and peptide mapping after enzymatic digestion separates melanotan II from closely related analogues. Quantitation of seized material is complicated by unknown counter-ions and residual trifluoroacetate left from purification. Immunoassays raised against alpha-melanocyte-stimulating hormone can cross-react, so chromatographic confirmation is normally required. Urinary detection windows are short, and reported limits of detection differ substantially between laboratories.
Melanotan II holds no marketing authorisation from the Food and Drug Administration, the European Medicines Agency, the UK Medicines and Healthcare products Regulatory Agency or Australia's Therapeutic Goods Administration. Products sold under that name are treated as unapproved new drugs, and their sale or import is prohibited in several jurisdictions. Other countries classify the peptide as a prescription-only medicine or place it among controlled substances, so the legal position changes with the destination market. No pharmacopoeial monograph supplies an official specification, because the material is not a licensed pharmaceutical. Consequently, products offered online are not manufactured to a shared public standard.
Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.
Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.
oligosaccharide A polymeric carbohydrate molecule consisting of a relatively short chain of connected monosaccharides. Oligosaccharides have important functions in processes such as cell signaling and cell adhesion. Longer chains are called polysaccharides.
The Treaty of Küçük Kaynarca authorised the Russian ambassador in Istanbul to defend the autonomy of Moldavia and Wallachia (known as the Danubian Principalities) in 1774. Taking advantage of the Greek War of Independence, a Wallachian lesser nobleman, Tudor Vladimirescu, stirred up a revolt against the Ottomans in January 1821, but he was murdered in June by Phanariot Greeks. After a new Russo-Turkish War, the Treaty of Adrianople strengthened the autonomy of the Danubian Principalities in 1829, although it also acknowledged the sultan's right to confirm the election of the princes. Mihail Kogălniceanu, Nicolae Bălcescu and other leaders of the 1848 revolutions in Moldavia and Wallachia demanded the emancipation of the peasants and the union of the two principalities, but Russian and Ottoman troops crushed their revolt. The Wallachian revolutionaries were the first to adopt the blue, yellow and red tricolour as the national flag, which included the motto "Justice, Fraternity" (Dreptate, Frăție) to symbolise the bond between Wallachians and Moldavians. In Transylvania, most Romanians supported the imperial government against the Hungarian revolutionaries after the Diet passed a law concerning the union of Transylvania and Hungary. Bishop Andrei Șaguna proposed the unification of the Romanians of the Habsburg Monarchy in a separate duchy, but the central government refused to change the internal borders.
=== Nomenclature === The usage of Roman numerals rather than eponyms or systematic names was agreed upon during annual conferences (starting in 1955) of hemostasis experts. In 1962, consensus was achieved on the numbering of factors I–XII. This committee evolved into the present-day International Committee on Thrombosis and Hemostasis (ICTH). Assignment of numerals ceased in 1963 after the naming of Factor XIII. The names Fletcher Factor and Fitzgerald Factor were given to further coagulation-related proteins, namely prekallikrein and high-molecular-weight kininogen, respectively. Factor VI is unassigned, as accelerin was found to be activated Factor V.
===== Macroscopic viscous flow ===== Macroscopic viscous flow fields can direct self-assembly of a random solution of particles into ordered crystals via the shear-assisted nucleation mechanism. However, the flow-induced self-assembly often occurs far from thermodynamic equilibrium and leads to amorphous aggregates of nanoparticles through a mechanism by which the shear flow field overcomes the repulsive energy barrier which stabilizes the nanoparticles against self-assembly in the absence of flow. The assembled particles aggregates tend to disassemble due to flow-induced breakup or when the flow is stopped or removed if the interparticle bonds are weak. Shear flows are also useful for jammed suspensions or random close packing. As these systems begin in nonequilibrium conditions, flow fields are useful in that they help the system relax towards a more ordered equilibrium. Flow fields are also useful when dealing with complex matrices that themselves exhibit rheological behavior. Flow can induce anisotropic viseoelastic stresses, which helps to overcome the matrix and cause self-assembly.
== History == Historically, the fish processing methods used for human consumption have been: fresh, canned, frozen, smoked or dehydrated - all of which would be used as a whole food rather than as an ingredient in other foods. Additionally, an industrial fish industry exists where whole fish and by products from fish processing have been cooked and dehydrated to form a product termed fish meal, which is used for animal feed, pet food and fish feed. With the evolution of refining and processing technology and expanded research on the nutrition of fish proteins and peptides, a new industry has developed for the specific purpose of producing a fish protein powder for human consumption with the intent of reaching new ingredient uses and markets. The FPP end product is now used in a variety of food ingredient applications including sports nutrition, food additives and supplements, all of which depend on the finished fish protein powder produced such that it is hygienically safe and also meets sensory requirements of taste, odor and function in prepared foods.
Sources: en.wikipedia.org
Low Apgar scores, <5 at 5 minutes and 10 minutes. Floppiness, or unreactive to sights or sounds, or more tense and agitated. Low heart rate. Low blood pressure. Poor muscle tone and absent reflexes. Weak breathing, no breathing at all, or rapid breathing. Need for resuscitation after delivery. Weak cry. Bluish or pale skin color. Excessive acid in the blood. Seizures or abnormal movements. Problems feeding
1993/2924) Social Security (Contributions) Amendment (No. 7) Regulations 1993 (S.I. 1993/2925) Dundee Healthcare National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2926) Falkirk and District Royal Infirmary National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2927) Hairmyres and Stonehouse Hospitals National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2928) Law Hospital National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2929) Perth and Kinross Healthcare National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2930) East and Midlothian National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2931) Royal Infirmary of Edinburgh National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2932) Western General Hospitals National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2933) Dumfries and Galloway Acute and Maternity Hospitals National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2934) Glasgow Community and Mental Health Services National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2935) Edinburgh Sick Children's National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2936) Fife Healthcare National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2937) Edinburgh Healthcare National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2938) Petroleum Revenue Tax (Nomination Scheme for Disposals and Appropriations) (Amendment) Regulations 1993 (S.I.
Edward Calvin Kendall (March 8, 1886 – May 4, 1972) was an American biochemist. In 1950, Kendall was awarded the Nobel Prize for Physiology or Medicine along with Swiss chemist Tadeusz Reichstein and Mayo Clinic physician Philip S. Hench, for their work with the hormones of the adrenal glands. Kendall not only researched the adrenal glands, he also isolated thyroxine, a hormone of the thyroid gland and worked with the team that crystallized glutathione and identified its chemical structure. Kendall was a biochemist at the Graduate School of the Mayo Foundation at the time of the Nobel award. He received his education at Columbia University. After retiring from his job with the Mayo Foundation, Kendall joined the faculty at Princeton University, where he remained until his death in 1972. Kendall Elementary School, in Norwalk is named for him.
=== RNA was likely critical for prebiotic evolution === The discovery of catalytic RNA (ribozymes) showed that RNA could both encode genetic information (like DNA) and catalyze specific biochemical reactions (like protein enzymes). This realization led to the RNA World Hypothesis, a proposal that RNA may have played a critical role in prebiotic evolution at a time before the molecules with more specialized functions (DNA and proteins) came to dominate biological information coding and catalysis. Although it is not possible for us to know the course of prebiotic evolution with any certainty, the presence of functional RNA molecules with common ancestry in all modern-day life forms is a strong argument that RNA was widely present at the time of the last common ancestor.
=== Influence on the Democratic Party === Analysts have suggested that Sanders's campaign shifted both the Clinton campaign and the Democratic Party politically leftward. A new political organization, Brand New Congress, was formed in April 2016 by former campaign staffers. It works to elect congressional representatives with platforms in line with Sanders. In August 2016, he formed Our Revolution, a political organization dedicated to educating voters about issues, getting people involved in the political process, and electing progressive candidates for local, state, and national office. Speaking on the PBS Newshour about the upcoming 2018 elections and discussing the main principles of the two major parties, Susan Page described the Republican Party as "Trump's party" and the Democratic Party as "Bernie Sanders's party", saying that "Sanders and his more progressive stance has really taken hold." Noting the increasing acceptance of his national single-payer health-care program, his $15-an-hour minimum wage stance, free college tuition, and many of the other campaign platform issues he introduced, an April 2018 opinion article in The Week suggested, "Quietly but steadily, the Democratic Party is admitting that Sanders was right." In July 2016, a Slate article called the Democratic platform draft "a monument to his campaign", noting not only his call for a $15 minimum wage but other campaign issues, such as Social Security expansion, a carbon tax, Wall Street reform, opposition to the death penalty, and a "reasoned pathway for future legalization" of marijuana.
Sources: en.wikipedia.org
Laboratory confirmation typically combines retention time matching on a chromatographic system with mass measurement. A reference standard of known identity is needed for a meaningful comparison. Sequence-level techniques can add further confirmation.
There is no single harmonised standard governing these products, and manufacturing conditions differ. Impurities may include truncated sequences, oxidation products, residual solvents, and counter-ions. Independent testing is often the only way to characterise a given lot.
Reported studies have looked at pigmentation, photoprotection, and metabolic or appetite-related endpoints in small experimental settings. Much of the evidence base is early-stage and limited in size. Questions about long-term effects and clinical relevance remain open.
No regulatory agency has authorised melanotan-2 as a medicine for any indication. It circulates mainly as a research chemical or through unregulated channels. As a result, identity, purity and content are not independently guaranteed.